Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer

Acta Oncologica

Volumn 53, Issue 10, 2014, Pages 1440-1445

  Tuxen, Malgorzata K ^a   Cold, Soeren ^b   Tange, Ulla B ^c   Balslev, Eva ^a   Nielsen, Dorte L ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c University of Copenhagen   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; TRASTUZUMAB; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; MACROGOL DERIVATIVE; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANAPHYLAXIS; ARTHRALGIA; AXILLARY LYMPH NODE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL EXAMINATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HEART INJURY; HUMAN; HUMAN TISSUE; LETTER; LYMPH NODE DISSECTION; MAMMOGRAPHY; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MYALGIA; NEUROTOXICITY; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL EXAMINATION; SENTINEL LYMPH NODE BIOPSY; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT THERAPY; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMISTRY; CLINICAL TRIAL; DRUG ADMINISTRATION; FEASIBILITY STUDY; MIDDLE AGED; PATHOLOGY; PROCEDURES; SAMPLE SIZE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; POLYETHYLENE GLYCOLS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SAMPLE SIZE; TAXOIDS;

EID: 84911911610     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2014.921727     Document Type: Letter

References (30)

1. Von Minckwitz G, Kaufmann M, Kuemmel S, Fasching PA, Eiermann W, Blohmer JU, et al., for the GBG and AGO-B Study Groups. Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. J Clin Oncol 2011; 29(Suppl): 1028.
2. Montagna E, Bagnardi V, Rotmensz N, Viale G, Pruneri G, Veronesi P, et al. Pathologic complete response after preoperative systemic therapy and outcome: Relevance of clinical and biologic baseline features. Breast Cancer Res Treat 2010; 124: 689-99.
3. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project protocol B-27. J Clin Oncol 2006; 24: 2019-27.
4. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol 2012; 19: 1508-16.
5. ®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15: 440-9.
6. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trial 1989; 10: 1-10.
7. Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluoro-uracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999; 17: 3412-7.
8. Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-7.
9. Bujanda DA, Sarmiento UB, Suarez MAC, Ruiz MP, Gonzalez MAL, Morales JA. Epirubicin, cyclophosphamide and weekly paclitaxel as neoadjuvant chemotherapy for stage II and III breast cancer. J Cancer Res Clin Oncol 2006; 132: 332-8.
10. Evans TR, Yellowlees A, Foster E, Earl H, Cameron DA, Hutcheon A W, et al. Phase III randomized trial of doxorubicin and docetaxel versus doxorubicin and cyclophosphamide as primary medical therapy in women with breast cancer: An Anglo-Celtic Cooperative Oncology Group study. J Clin Oncol 2005; 23: 2988-95.
11. Kelly H, Kimmick G, Dees EC, Collichio F, Gatti L, Sawyer L, et al. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006; 7: 237-43.
12. Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, et al. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. Anticancer Drugs 2006; 17: 1201-9.
13. Tiezzi DG, Andrade JM, Ribeiro-Silva A, Zola FE, Marana HR, Tiezzi MG. HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007; 7: 36.
14. Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, et al. Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: A phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 2002; 13: 1737-42.
15. Rossi D, Baldelli AM, Casadei V, Fedeli SL, Alessandroni P, Catalano V, et al. Neoadjuvant chemotherapy with low dose of pegylated liposomal doxorubicin plus weekly paclitaxel in operable and locally advanced breast cancer. Anticancer Drugs 2008; 19: 733-7.
16. Artioli G, Mocellin S, Borgato L, Cappetta A, Bozza F, Zavagno G, et al. Phase II study of neoadjuvant gemcitabine, pegylated liposomal doxorubicin, and docetaxel in locally advanced breast cancer. Anticancer Res 2010; 30: 3817-21.
17. Dellapasqua S, Mazza M, Rosa D, Ghisini R, Scarano E, Torrisi R, et al. Pegylated liposomal doxorubicin in combination with low-dose metronomic cyclophosphamide as preoperative treatment for patients with locally advanced breast cancer. Breast 2011; 20: 319-23.
18. Taguchi T, Masuda N, Nakayama T, Motomura K, Tsukamoto F, Shimazu K, et al. Phase II trial in Japan of sequential administration of weekly paclitaxel followed by FEC as neoadjuvant chemotherapy for locally advanced breast cancer (KBCSG0206 trial: Kinki Breast Cancer Study Group (KBCSG)). Oncology 2010; 78: 302-8.
19. Therasse P, Mauriac L, Welnicka-Jaskiewicz M, Bruning P, Cufer T, Bonnefoi H, et al. Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: An EORTC-NCIC-SAKK multicenter study. J Clin Oncol 2003; 21: 843-50.
20. Gianni L, Semiglazov V, Manikhas GM, Eiermann W, Lluch A, Tjulandin S, et al. Neoadjuvant trastuzumab in locally advanced breast cancer (NOAH): Antitumour and safety analysis. J Clin Oncol 2007; 25(Suppl): 532 (abstract)
21. Gianni L, Eiermann W, Semiglazov V, Manikhas A, Lluch A, Tjulandin S, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): A randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-84.
22. Berrutoni A, Brizzi MP, Generali D, Ardine M, Dogliotti L, Bruzzi P, et al. Presurgical systemic treatment of nonmetastatic breast cancer: Facts and open questions. Oncologist 2008; 13: 1137-48.
23. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
24. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
25. Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
26. Bowles EJA, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J Nat Cancer Inst 2012; 104: 1293-305.
27. Chia S, Clemons M, Martin LA, Rodgers A, Gelmon K, Pond GR, et al. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: A multicentre phase II trial. J Clin Oncol 2006; 24: 2773-8.
28. Liedtke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 2009; 20: 1953-8.
29. Lindström L, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are instable throughout tumor progression. J Clin Oncol 2012; 30: 2601-8.
30. Curigliano G, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurillo G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice? Ann Oncol 2011; 22: 2227-33.